FDA approves Ionis ZANVASTRO, first treatment for Alexander disease
The FDA approved Ionis Pharmaceuticals' ZANVASTRO (zilganersen) on September 3, 2026, as the first disease-modifying treatment for Alexander disease. The RNA-targeted therapy reduces the protein that accumulates in astrocytes and is dosed every 12 weeks.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@PrismMarketView
The FDA approved Ionis $IONS ZANVASTRO on September 3, the first disease-modifying treatment for Alexander disease. The RNA-targeted therapy reduces the protein that accumulates in astrocytes and drives the disease, dosed every 12 weeks. Roughly one in one to three million people
@0x_illuminati
you have no idea how much better it is getting - ionis: zilganersen, first alexander disease treatment. so it begins - ctx310: ldl -52% for 1 year, 15 people (cleveland clinic) - berkeley: semaglutide +100 days in old female mice this is week 1 of september 2026 bio/acc